Stemming from these unbiased screens, as well as a growing body of literature suggesting D2Rs can function as tumor promoters, DRD2 antagonists have been investigated for efficacy in cancer treatment, and multiple D2R antagonists are currently in clinical trials [21]. This evidence concerns the gene DRD2 and cancer.